Heparin Articles

NORMIFLO REJECTED BY FDA

20 December 1993

RESEARCH AND INVESTMENT IN CARDIOLOGY

20 December 1993

PHASE II TRIAL OF REPLIGEN'S rPF4

6 December 1993

NEW DATA ON ACTIVASE FROM GUSTO TRIAL

29 November 1993

RESULTS FROM PHASE II TIMI-5 STUDY

22 November 1993

GLYCOMED PATENT

25 October 1993

NEW TRIAL RESULTS REPORTED AT ECCO

20 September 1993

THROMBOLYSIS DEBATE RESTARTS WITH GUSTO

13 September 1993

PENDING APPLICATIONS IN US CONTINUE TO DWINDLE

19 July 1993

IMMUNOTHERAPEUTICS IN AIDS THERAPY

5 July 1993

WELLCOME HALTS FLOLAN DEVELOPMENT FOR CHF

28 June 1993

COR'S INTEGRELIN: PHASE II RESULTS

14 June 1993

T-PA BACKED BY GUSTO STUDY RESULTS

10 May 1993

STRONG FIRST QUARTER FOR R-PR

26 April 1993

NOVO NORDISK EXPANDING ITS FOCUS

26 April 1993

FIRST LOW MOLECULAR WEIGHT HEPARIN IN USA

19 April 1993

AMERICAN HOME HAS CONFIDENCE FOR 1993

12 April 1993

PROCORDIA/KABI PHARMACIA PROFITS UP

22 March 1993

FRAGMIN SAFER THAN STANDARD HEPARIN

8 February 1993

NEW REPLIGEN IND

25 January 1993

THROMBOEMBOLISM PREVENTION MARKET

4 January 1993

ISRAEL CONSIDERS KORATH INCLUSIONS

4 January 1993

AMERICAN HOME: FINALLY A PHARMA COMPANY

7 December 1992

REVENUES DECLINE, R&D UP AT SCIOS IN 1991

4 May 1992

PROJECT REVIEW FROM NOVO NORDISK

27 April 1992

ELI LILLY BUYS STAKE IN BEIERSDORF GmbH

27 April 1992

STOCK MARKET COMMENTARY: TOKYO

20 April 1992

GENENTECH REBUFFS ISIS-3 AND AWAITS GUSTO

6 April 1992

GENENTECH REBUFFS ISIS-3 AND AWAITS GUSTO

6 April 1992

China blames Baxter for heparin deaths